Use of disphosphonates in the treatment of osteoporosis in thyroidectomized patients on levothyroxin replacement therapy

被引:11
|
作者
Panebianco, P [1 ]
Rosso, D [1 ]
Destro, G [1 ]
Scarpinato, RA [1 ]
Tropea, S [1 ]
Rizzo, A [1 ]
Russo, MS [1 ]
Motta, M [1 ]
DiStefano, F [1 ]
Mazzarella, R [1 ]
Maugeri, D [1 ]
机构
[1] UNIV CATANIA,OSPED CANNIZZARO,INST INTERNAL MED & GERIATR,I-95126 CATANIA,ITALY
关键词
bone mineral density; osteoporosis; disphosphonates; L-T4; therapy;
D O I
10.1016/S0167-4943(97)00013-7
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Bone mineral density at medio distal (MD-BMD) and ultra distal (UD-BMD) sites of non dominant radius were studied, using a DEXA Mineralometer (TURBOSCAN-NIM) on a series of 20 patients, over 60 years old, all thyroidectomized for thyroid carcinoma and treated with levothyroxin replacement therapy. T3 and T4 (RIA method), TSH (IRMA method) and two cardiac parameters as TPER (time peak ejection rate) and TPFR (time peak filling rate) by angiocardioscintigraphy were also determined. Results showed that 19 patients considering MD-BMD values and ten considering UD-BMD values were at risk of fractures. Circulating T3 levels were within normal range in 17 patients, elevated in two cases and reduced in one case. Circulating T4 levels were within normal range in 15 patients, increased in four cases and reduced in one case. Circulating TSH levels were within normal range in 17 patients, reduced in two cases and elevated in one case. TPER were reduced in 18 patients and normal in two cases. TPFR were reduced in six patients and normal in fourteen cases. The authors administered alendronate (10 mg/day) which seems to prevent bone loss, especially at the level of the trabecular bone. Bone loss reverted at 6 and 12 months, confirming that disphosphonates slow down this phenomenon in a situation of increased bone turnover (e.g. patients on long-term L-T4 therapy). (C) 1997 Elsevier Science Ireland Ltd.
引用
收藏
页码:219 / 225
页数:7
相关论文
共 50 条
  • [31] Compliance with continuous low dose hormone replacement therapy for the treatment of osteoporosis.
    Ridout, R
    Hawker, GA
    Garcia, Y
    Rubin, LA
    ARTHRITIS AND RHEUMATISM, 1996, 39 (09): : 659 - 659
  • [32] Correlation between the bone mineral density and TSH in patients on levothyroxin treatment
    Giorgadze, E.
    Chachibaia, V
    Tsagareli, M.
    Jikurauli, N.
    Tsagareli, N.
    OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S243 - S243
  • [33] The health economics of osteoporosis and estrogen replacement therapy
    Prince, RL
    PROGRESS IN THE MANAGEMENT OF THE MENOPAUSE, 1997, : 170 - 174
  • [34] Hormone replacement therapy and the prevention of postmenopausal osteoporosis
    Gambacciani, Marco
    Levancini, Marco
    MENOPAUSE REVIEW-PRZEGLAD MENOPAUZALNY, 2014, 13 (04): : 213 - 220
  • [35] Carcinoma of the breast and hormone replacement therapy for osteoporosis
    Crawshaw, A
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2000, 54 (02) : 99 - 103
  • [37] Use of testosterone replacement therapy in patients with prostate cancer
    Dorff T.B.
    Vogelzang N.J.
    Current Urology Reports, 2011, 12 (3) : 223 - 228
  • [38] THE USE OF TUBERCULOSIS CHEMOPROPHYLAXIS IN PATIENTS OF RENAL REPLACEMENT THERAPY
    Ahern, N.
    Jarvis, H.
    Charif, R.
    Kon, O. M.
    THORAX, 2016, 71 : A51 - A51
  • [39] WILLINGNESS TO INITIATE HORMONE REPLACEMENT THERAPY FOR PREVENTION OR TREATMENT OF OSTEOPOROSIS - IDENTIFICATION OF PATIENT SUBSETS
    SEBALDT, RJ
    ADACHI, JD
    GORDON, M
    STEELE, M
    JOURNAL OF BONE AND MINERAL RESEARCH, 1995, 10 : S252 - S252
  • [40] The pathophysiology and treatment of postmenopausal osteoporosis - An evidence-based approach to estrogen replacement therapy
    Rosen, CJ
    Kessenich, CR
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 1997, 26 (02) : 295 - +